02
December
2014
|
00:00
Europe/Amsterdam

BIOTRONIK Announces Completion of Enrollment in BIOHELIX-I Clinical Trial Evaluating Safety and Efficacy of PRO-Kinetic Energy Stent

LAKE OSWEGO, Oregon, December 2, 2014—BIOTRONIK, a leading manufacturer of innovative cardio- and endovascular medical technology, announced that the final patient has been enrolled in the BIOHELIX-I clinical trial. The BIOHELIX–I trial is designed to evaluate the safety and efficacy of the PRO-Kinetic Energy coronary bare metal stent and supports US Food and Drug Administration approval for the treatment of coronary arteries. BIOTRONIK previously received CE mark approval for PRO-Kinetic Energy in 2009.

“The ultra-thin strut PRO-Kinetic Energy stent has a low profile and is extremely deliverable,” commented national principal investigator for the study Dr. Saurabh Gupta, Director of the Cardiac Catheterization Laboratory at Oregon Health & Science University, Portland, Oregon. “I look forward to this innovative technology being available to all of my patients requiring treatment with a bare metal stent.”

The BIOHELIX-I prospective, non-randomized, multi-center study (NCT01612767) has enrolled 329 patients in the US, Europe and South America. The primary endpoint for the study is the rate of target vessel failure nine months after stent implantation, a composite endpoint encompassing cardiac death, myocardial infarction and ischemia-driven target
vessel revascularization.

PRO-Kinetic Energy is an ultrathin strut (60μm / 0.0024“) cobalt chromium, bare metal stent, completely sealed with a thin layer of amorphous silicon carbide, called proBIO. This passive coating is known to reduce metal ion release from the stent, limiting adverse events post-implantation.

PRO-Kinetic Energy was previously evaluated for safety and effectiveness in the ENERGY registry, an all-comers registry, which studied more than 1,000 patients in Europe and Israel. The ENERGY registry studied more than 1,000 patients with a complex population of 39% B2/C lesions and 46% acute coronary syndrome patients. At 12 months, PRO-Kinetic Energy demonstrated a low 8.8% major adverse cardiac events (MACE) rate, including a 3.4% rate of target lesion revascularization (TLR). A sub-group analysis showed similarly low 12-month MACE rates in acute coronary syndrome (ACS) patients, elderly patients, and patients with small
vessels or diabetes.

“The PRO-Kinetic Energy stent has already proven itself as an excellent treatment option for over half a million patients,” said Dr. Daniel Buehler, President, BIOTRONIK Vascular Intervention. “The BIOHELIX-I trial brings BIOTRONIK one step closer to achieving its goal of offering US physicians a complete portfolio of innovative solutions for treating coronary disease.”

  1. CAUTION – Investigational device. Limited by United States law to
    investigational use.
  2. Not currently available in the United States.

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.